TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05236530
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.
Study: NCT05007106
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles
Study: NCT05442047
Drug: NNC6019-0001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive i.v infusionof NNC6019-0001.
Study: NCT05442047
Drug: Placebo (NNC6019-0001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive i.v. infusion of placebo (NNC6019-0001).
Study: NCT05472779
Drug: Periurethral application of estradiol cream
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.
Study: NCT05472779
Drug: Intravaginal application of estradiol cream
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will apply 1 gram estradiol cream intravaginally using an applicator.
Study: NCT05192941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to inclisiran 300 mg subcutaneously
Study: NCT06560645
Drug: PRT7732
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT7732 capsules will be self-administered once daily at the dose-level assigned
Study: NCT06559969
Drug: Intravenous administered opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone will be received intravenously using a patient controlled administration pump, as well as patient will have a continuous bupivacaine epidural infusion
Study: NCT06087913
Drug: TAF/EVG vaginal insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal insert applied daily for 3 days then every other day for 14 days
Study: NCT06087913
Drug: Matching Placebo vaginal insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal insert applied daily for 3 days then every other day for 14 days
Study: NCT05438797
Drug: Adoptive TIL-TCM transfer therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abraxane:100-200 mg/m2，QD×1D;Cyclophosphamide:15-35 mg/kg/d，QD×2D. Biological: Adoptive TIL-TCM transfer therapy
Study: NCT06141070
Drug: Standard systemic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy or immunotherapy
Study: NCT05262101
Drug: TQB2858 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
Study: NCT05856487
Drug: NVP-2203 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT05856487
Drug: NVP-2203-R1 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT05856487
Drug: NVP-2203-R2 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT05856487
Drug: NVP-2203-R3 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT05921890
Drug: GS3-007 oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage was calculated according to body weight, once a day or twice a day.
Study: NCT06180720
Drug: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
Study: NCT06180720
Drug: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
Study: NCT06196879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verekitug (UPB-101) matching placebo
Study: NCT05639647
Drug: ATM-AVI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A drug specifically designed to treat resistant gam-negative bacterial infections
Study: NCT05295589
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05814835
Drug: 2-4 mCi 68Ga/64Cu-FAPI-XT117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
Study: NCT05814835
Drug: 4-6 mCi 68Ga/64Cu-FAPI-XT117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
Study: NCT05814835
Drug: 6-8 mCi 68Ga/64Cu-FAPI-XT117
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
Study: NCT06158269
Drug: DVRd
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
Study: NCT00431548
Drug: 100% O2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06093425
Drug: TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All medications administered intravenously
Study: NCT06093425
Drug: Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All medications administered intravenously
Study: NCT06525168
Drug: DA414 Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.
Study: NCT06525168
Drug: DA414 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.
Study: NCT06491550
Drug: Placebo- Part A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.
Study: NCT03953170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06491550
Drug: Placebo- Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.
Study: NCT06491550
Drug: Rosuvastatin and Furosemide- Part C
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.
Study: NCT06491550
Drug: Rosuvastatin, Furosemide, and AZD4144 Part C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.
Study: NCT05486026
Drug: Nonsteroidal Antiinflammatory Drug
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient in this second group will receive NSAID for 3 weeks
Study: NCT06026397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive oral suspension of placebo, includes SAD on Day 1 and 14-days MAD from Day 4 to Day 17.
Study: NCT06039202
Drug: CA102N
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim)
Study: NCT05838066
Drug: HB1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04789499
Drug: Theophylline Powder
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
Study: NCT04789499
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
Study: NCT06441578
Drug: Recombinant ADAMTS13
Normalized name: ADAMTS13, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant ADAMTS13, Intravenous injection
Study: NCT04929483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05153434
Drug: ARD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice Daily, Oral Administration
Study: NCT05631626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05613400
Drug: Simvastatin 10mg
Normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One simvastatin 10mg-tablet
Study: NCT05003648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT06215859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: over-encapsulated tablet and/or tablet
Study: NCT05276596
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately use of norepinephrine by intravenous injection using an electric syringe pump, at a dilution of 0.016 mg / ml, at the time of anesthetic induction and without waiting the 1st possible arterial hypotension. Noradrenaline will be started at a dose of 0.48 mg / h and then adapted according to the blood pressure objectives.
Study: NCT05369767
Drug: SAD, SHR-2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dose
Study: NCT05369767
Drug: SAD, SHR-2004 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dose
Study: NCT06408857
Drug: MAM01 300 mg SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAM01 300 mg will be administered SC
Study: NCT05909267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients and healthy controls will receive one time administration of Placebo.
Study: NCT06408857
Drug: MAM01 300 mg IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAM01 300 mg will be administered IM route
Study: NCT06408857
Drug: MAM01 2000 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAM01 2000 mg will be administered IV
Study: NCT06408857
Drug: MAM01 190 mg SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAM01 190 mg will be administered SC
Study: NCT06408857
Drug: MAM01 100 mg SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAM01 100 mg will be administered SC
Study: NCT03564548
Drug: PPP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group assigned to PPP001
Study: NCT06408857
Drug: MAM01 150 mg IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAM01 150 mg will be administered IM
Study: NCT06408857
Drug: MAM01 150 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAM01 150 mg will be administered IV
Study: NCT06408857
Drug: Placebo IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered IM
Study: NCT04999488
Drug: BPM31510
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
Study: NCT04440592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05064319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
Study: NCT04897802
Drug: Experimental: GLP1-RA (exenatide) administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
Study: NCT06514339
Drug: shenhuang granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine compound Shenhuang Granules is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification.
Study: NCT06514339
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.
Study: NCT05123196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05593588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
Study: NCT04933565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules
Study: NCT05412082
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
Study: NCT05412082
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
Study: NCT05318326
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Study: NCT05318326
Drug: Yogliptin 400mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogliptin 400mg (4 tablet) , Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Study: NCT05318326
Drug: Yogliptin 200mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogliptin 200mg (2 tablet) and placebo 200 mg (2 tablet), Q1W, oral, week 1 to week 24; Yogliptin 400 mg (4 tablet), Q1W, oral, week 25 to week 52.
Study: NCT04502433
Drug: CUROSURF® (poractant alfa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW.
Study: NCT06228339
Drug: Xatral® XL 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xatral® XL 10 mg (Reference Drug)
Study: NCT05397652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients from experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously unlike the patients in the control group who will receive just sterile saline.
Study: NCT05559268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml (60 mg) subcutaneous injection Saline give in the posterior part of the upper arm after TKA
Study: NCT06138795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
Study: NCT06068608
Drug: TNM005
Approvals — FDA: no, EMA: no, PMDA: no
Description: single,intramuscular injection
Study: NCT06068608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single,intramuscular injection
Study: NCT03797612
Drug: Placebo 6 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative intrathecal injection
Study: NCT04674956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 200mg, D1; every 21 days as a cycle.
Study: NCT05917340
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering dose of dexamethasone or prednisolone upto 8 weeks
Study: NCT05389267
Drug: Kinezodianone R hydrochloride
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyedrops
Study: NCT05389267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05107115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral use
Study: NCT05560360
Drug: SHR1459 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/tablet; administered orally
Study: NCT06403943
Drug: BaiDiZiYin Pill, ShenQiYiFei Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indications of BaidiZiyin Pill: Nourishing the lungs and kidneys, cooling blood and removing steam. Used as an adjunctive treatment for tuberculosis caused by lung and kidney deficiency and qi yin injury, including coughing, shortness of breath, dry cough with less phlegm, hot flashes and night sweats, cold and spontaneous sweating, hoarseness, palpitations, cold limbs, and emaciation.~Indications of ShenqiYifei Pill: expectorant and cough relieving. It is suitable for patients with pulmonary tuberculosis and spleen diseases, as well as phlegm dampness retention. Symptoms include short breath, low sound, clear and thin phlegm, limited appetite, bloating and loose stools, pale complexion, fatigue and chest tightness, emaciation, and fear of cold and spontaneous sweating.
Study: NCT06403943
Drug: Anti tuberculosis chemotherapy
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 months' intensive regimen of anti tuberculosis chemotherapy Recommended first-line anti tuberculosis regimen: 2HRZE
Study: NCT04479072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Study: NCT04617171
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
Study: NCT06556732
Drug: Eplereone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Study: NCT05833815
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: GemOx or CapOx
Study: NCT06064812
Drug: FWD1802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days.
Study: NCT05545735
Drug: Standard of Care Antibiotic Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics will be administered as per the standard of care orally via tablet
Study: NCT05481307
Drug: RLD2203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once a day per period
Study: NCT05166876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, 100 mg, 150 mg, 200 mg x 5 days
Study: NCT05363774
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels.
Study: NCT05363774
Drug: Placebo (NNC0519-0130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels.
Study: NCT04908748
Drug: Esflurbiprofen Hydrogel Patch
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esflurbiprofen is a cyclooxygenase (COX) inhibitor
Study: NCT05755438
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
Study: NCT05607615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5N saline as an intravenous (IV) infusion once every 28 days
Study: NCT04862819
Drug: new local drug delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp